{"id":95500,"date":"2023-06-21T17:00:00","date_gmt":"2023-06-21T17:00:00","guid":{"rendered":"https:\/\/quixnet.net\/2023\/06\/fda-approves-first-gene-therapy-for-treatment-of-certain-patients-with-duchenne-muscular-dystrophy-fda-gov\/"},"modified":"2023-06-21T17:00:00","modified_gmt":"2023-06-21T17:00:00","slug":"fda-approves-first-gene-therapy-for-treatment-of-certain-patients-with-duchenne-muscular-dystrophy-fda-gov","status":"publish","type":"post","link":"https:\/\/quixnet.net\/wpinstance\/fda-approves-first-gene-therapy-for-treatment-of-certain-patients-with-duchenne-muscular-dystrophy-fda-gov\/","title":{"rendered":"FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy – FDA.gov"},"content":{"rendered":"
\n
    \n
  1. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy<\/a>FDA.gov<\/font><\/li>\n
  2. First Gene Therapy for Muscular Dystrophy Approved<\/a>The Wall Street Journal<\/font><\/li>\n
  3. Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy<\/a>Business Wire<\/font><\/li>\n
  4. Sarepta’s DMD gene therapy secures accelerated FDA approval<\/a>FiercePharma<\/font><\/li>\n
  5. FDA grants conditional approval to Sarepta’s gene therapy for Duchenne muscular dystrophy<\/a>STAT<\/font><\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular DystrophyFDA.gov First Gene Therapy for Muscular Dystrophy ApprovedThe Wall Street Journal Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular DystrophyBusiness Wire Sarepta’s DMD gene therapy secures accelerated FDA approvalFiercePharma FDA grants conditional approval to Sarepta’s […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[6],"tags":[],"class_list":{"0":"post-95500","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business","7":"entry"},"_links":{"self":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/posts\/95500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/comments?post=95500"}],"version-history":[{"count":0,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/posts\/95500\/revisions"}],"wp:attachment":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/media?parent=95500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/categories?post=95500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/tags?post=95500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}